

## N-Acetylcysteine Administration Prevents Nonthyroidal Illness Syndrome in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial

Josi Vidart, Simone Magagnin Wajner, Rogério Sarmiento Leite, André Manica, Beatriz D. Schaan, P. Reed Larsen, and Ana Luiza Maia

Thyroid Unit (J.V., S.M.W., B.D.S., A.L.M.), Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, CEP 90620-000, Porto Alegre, RS, Brasil; Instituto de Cardiologia do RS/Fundação Universitária de Cardiologia (R.S.L., A.M.); and Division of Endocrinology, Diabetes, and Hypertension (P.R.L.), Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115

**Context:** The acute phase of the nonthyroidal illness syndrome (NTIS) is characterized by low  $T_3$  and high  $rT_3$  levels, affecting up to 75% of critically ill patients. Oxidative stress has been implicated as a causative factor of the disturbed peripheral thyroid hormone metabolism.

**Objective:** The objective of the study was to investigate whether N-acetylcysteine (NAC), a potent intracellular antioxidant, can prevent NTIS in patients with acute myocardial infarction.

**Design:** This was a randomized, multicenter clinical trial.

**Settings:** Consecutive patients admitted to the emergency and intensive care units of two tertiary hospitals in southern Brazil were recruited. Patients and intervention included 67 patients were randomized to receive NAC or placebo during 48 hours. Baseline characteristics and blood samples for thyroid hormones and oxidative parameters were collected.

**Main Outcome:** Variation of serum  $T_3$  and  $rT_3$  levels was measured.

**Results:** Baseline characteristics were similar between groups (all  $P > .05$ ).  $T_3$  levels decreased in the placebo group at 12 hours of follow-up ( $P = .002$ ) but not in NAC-treated patients ( $P = .10$ ). Baseline  $rT_3$  levels were elevated in both groups and decreased over the initial 48 hours in the NAC-treated patients ( $P = .003$ ) but not in the control group ( $P = .75$ ). The free  $T_4$  and TSH levels were virtually identical between the groups throughout the study period ( $P > .05$ ). Measurement of total antioxidant status and total carbonyl content demonstrated that oxidative balance was deranged in acute myocardial infarction patients, whereas NAC corrected these alterations ( $P < .001$ ).

**Conclusions:** NAC administration prevents the derangement in thyroid hormone concentrations commonly occurring in the acute phase of acute myocardial infarction, indicating that oxidative stress is involved in the NTIS pathophysiology. (*J Clin Endocrinol Metab* 99: 4537–4545, 2014)

**N**onthyroidal illness syndrome (NTIS) refers to characteristic changes in thyroid hormone levels that occur during acute and chronic severe illnesses. The acute phase of the syndrome is characterized by low serum total  $T_3$  and free  $T_3$ , as well as high  $rT_3$  concentrations. Serum  $T_4$  may be normal or reduced (1). Although serum TSH

remains in the normal range, the nocturnal surge of TSH observed in the normal physiological state is absent (2). In the acute phase of illness, the alterations occur primarily in the peripheral metabolism of thyroid hormones, whereas neuroendocrine abnormalities predominate in prolonged illness (1).

ISSN Print 0021-972X ISSN Online 1945-7197  
Printed in U.S.A.

Copyright © 2014 by the Endocrine Society

Received April 28, 2014. Accepted August 18, 2014.

First Published Online August 22, 2014

Abbreviations: AMI, acute myocardial infarction; D, deiodinase; FT<sub>4</sub>, free T<sub>4</sub>; GSH, glutathione; ICU, intensive care unit; NAC, N-acetylcysteine; NTIS, nonthyroidal illness syndrome; ROS, reactive oxygen species; TAS, total antioxidant; TIMI, Thrombolysis In Myocardial Infarction.

NTIS occurs in 30%–90% of patients with acute myocardial infarction (AMI) (3, 4). Low serum  $T_3$  levels are an independent marker of myocardial damage and poor prognosis during this clinical situation and are associated with increased morbidity and mortality in the short, medium, and long term (4–6). It has been postulated that low  $T_3$  levels in myocardial tissue can produce a state of local hypothyroidism, worsening the tissue damage and cardiac disease (4).

The pathophysiology of NTIS is complex. One of the putative mechanisms for changes in the thyroid hormone levels are derangements in iodothyronine deiodinases function (D1, D2, and D3) (7, 8). These selenoenzymes are a family of oxidoreductases that catalyze peripheral iodothyrosine deiodination. D1 and D2 convert  $T_4$  to the active hormone  $T_3$ , whereas it is the source of 80% of the peripheral levels of  $T_3$  (8). D3 inactivates both  $T_4$  and  $T_3$ . All three deiodinases require an as-yet-undefined cofactor, probably a thiol or thiol-dependent compound, which acts as a reducing agent releasing iodine from the selenocysteine residue and regenerating the active enzyme (8). It has been recently shown in a cell culture system that changes in the intracellular redox state can impair the thyroid hormone economy by altering the peripheral  $T_3/T_4$  activation/inactivation process (9). These alterations were prevented by the addition to the media of N-acetylcysteine (NAC), an antioxidant that increases the intracellular cysteine and reduced the glutathione (GSH) levels, thus restoring the redox equilibrium. NAC reestablished the activity of the deiodinases by restoring the intracellular cysteine levels and/or replenishing the enzyme thiol cofactor, perhaps GSH.

In the current study, we investigated whether early iv NAC administration would prevent the changes in thyroid hormone levels that are observed in patients with AMI.

## Subjects and Methods

### Eligibility and study design

This was a randomized, prospective, multicenter study (Clinical Trials number NCT01501110) to evaluate whether NAC can prevent the thyroid hormone changes as seen in NTIS after an AMI. Consecutive patients admitted to the emergency and intensive care units of two tertiary hospitals in southern Brazil were recruited. Patients with a diagnosis of AMI within 12 hours of evolution who underwent primary percutaneous coronary intervention were eligible. Myocardial infarction was defined by persistent new electrocardiographic ST elevation at the J point in at least in two contiguous leads of 2.0 mm (men) or 1.5 mm (women) with or without Q-wave formation and subsequent release of biomarkers of myocardial necrosis (10). Patients who met the following criteria were excluded: 1) age younger than 18 years or older than 80 years; 2) history of primary thyroid disease; 3) chronic use of corticosteroids; 4) chronic renal failure


requiring hemodialysis; 5) severe hepatic insufficiency, class C category in Child-Pugh score, or a score greater than 15 in the model for end-stage liver disease; 6) severe immunosuppression, defined as marrow or solid organ transplantation, severe leukopenia (white blood cell count  $< 1000/\text{mm}^3$ ), hematological malignancy, and immunodeficiency syndromes; and 7) pregnant women or women undergoing postmenopausal hormone replacement. Ten healthy subjects were included for baseline comparison of rT3 levels and oxidative stress and IL-6 measurements.

The Institutional Ethics Committees approved the study protocol and a written informed consent was obtained from all patients before randomization.

### Study protocol

Patients were randomly assigned to the use of NAC or placebo on the basis of a random number generator. Patients selected for the intervention group received five doses of 1200 mg (12 mL) of NAC by iv route, the first dose being administered prior to cardiac catheterization and every 12 for 48 hours after the procedure (total dose 6000 mg) (10, 11). Patients randomized to the control group received 0.9% normal saline iv (12 mL), every 12 hours, for 48 hours. Laboratory assessment was performed at baseline (time 0) and at 6, 12, 24, 48, and 120 hours after the first NAC administration. All other aspects of patient care were carried out at the discretion of the treating clinicians.

Participants were recruited during the period of July 2011 to September 2012. Eighty-three patients were assessed for eligibility. Thirteen patients were excluded: four patients had renal failure, seven had thyroid disease, two were receiving immunosuppression therapy, and two patients did not provide written consent. Thus, 68 patients participated in the study (Figure 1).



**Figure 1.** Consolidated Standards of Reporting Trials diagram depicting subject flow.

## Laboratory measurements

Venous blood samples were obtained at admission (baseline), after 6, 12, and 48 hours, and on the fifth day or at the time of hospital discharge if this occurs before the fifth day. Thyroid hormones and oxidative stress parameters were evaluated.

Assays were performed in duplicate on batched serum samples that had been stored at  $-20^{\circ}\text{C}$ , pending study completion. Serum total  $T_3$ ,  $T_4$ , free  $T_4$  (FT4), and TSH were measured by electrochemiluminescent immunoassay (ADVIA Centaur XP; Siemens). Serum  $rT_3$  levels were measured by an ELISA kit (USCN Life Science Inc). The interassay coefficients of variation were as follows:  $T_3$ , 7.1%;  $T_4$ , 10%; FT4, 7%; and  $rT_3$ , less than 10%. The intraassay coefficients of variation were as follows:  $T_3$ , 6.2%–7%;  $T_4$ , 3%–8%; FT4, 3%–6%; and  $rT_3$ , 6%–8%. Normal ranges were as follows: serum FT4, 0.7–1.5 ng/dL;  $T_4$ , 4.5–12 ng/dL;  $T_3$ , 77–180 ng/dL; and  $rT_3$ , 10–24 ng/dL.

Total antioxidant capacity (TAS) and carbonyl content and were measured in serum for assessment of oxidative stress and response to treatment with NAC. The quantitative determination of the total antioxidant status (TAS) was determined using the TAS kit (Randox, UK). ABTS 92,2'-azino diethyl-benzothiazoline sulfonic acid) was incubated with a peroxidase and  $\text{H}_2\text{O}_2$  to generate the cation 2,2'-azino diethyl-benzothiazoline sulfonic acid, a relatively stable blue-green compound measurable at 600 nm. The antioxidants present in the sample inhibit this reaction, producing a decrease in the color intensity, which is proportional to the total antioxidant concentration (12). Samples were run in triplicate and were expressed as percentage variation in the color intensity compared with control. For carbonyl measurement, duplicate aliquots of plasma (containing  $\sim 0.3$  mg of protein) were incubated with 500  $\mu\text{L}$  of 10 mM 2,4-dinitrophenylhydrazine or 1.0 mL of 2 M HCl (blank tube). After 30 minutes, 250  $\mu\text{L}$  of 50% trichloroacetic acid was added. The samples were centrifuged at  $8000 \times g$  for 30 minutes to obtain the protein pellets, which were immediately washed with ethanol-ethyl acetate 1:1 (vol/vol). The final protein pellets were diluted in 500  $\mu\text{L}$  of 8 M urea buffer and incubated at  $50^{\circ}\text{C}$  for 90 minutes. The difference between the 2,4-dinitrophenylhydrazine-treated and HCl-treated samples (blank) was used to calculate the carbonyl content determined at 370 nm. Carbonyl (CO) content was calculated using the millimolar absorption coefficient of hydrazone ( $\epsilon_{370\text{ nm}} = 2.1 \times 10^4 \text{ M}^{-1}\text{cm}^{-1}$ ), and the results were expressed in nanomoles of carbonyl per milligram protein measured by the Bradford method.

IL-6 measurements were performed according to the manufacturer's instructions on a Luminex 200 System (Luminex Corp). The Luminex protocol is a sandwich immunoassay system using magnetic beads. This method allows the detection of cytokines in a dual-laser flow analyzer. Human cytokine analysis kits were custom ordered (Invitrogen by Life Science) and included all necessary reagents for analysis. Briefly, cytokine antibody-conjugated beads were added to each well of a flat-bottom, 96-well plate. Plasma samples were thawed completely at room temperature, mixed well by vortexing, and centrifuged to remove precipitated material. Serum samples were diluted 1:2 with the provided diluents and pipetted into the wells, incubated, and washed appropriately. After final incubation and washing, fluorochrome bound to magnetic beads was quantified by the Luminex-200, calibrated using calibration microspheres. The median fluorescence intensity of fluorochrome-conjugated antibody bound to individual microspheres was derived from flow

analysis of 50 microspheres per region. Cytokine quantification was plotted via standard curves. The intensity of the fluorescence was directly proportional to the concentration of cytokine. Quality control was performed between the plates by using the controls provided in the kit. The assay was completed on the same day by the same person. The plate variation was 6.94% in this assay. IL-6 levels were calculated using the xPonent version 3.1 software package (Luminex Corp) and expressed as nanograms per liter. The detection limit for IL-6 measurement was 0.3 pg/mL.

## Outcome measures

The primary outcome measure was the change in plasma thyroid hormones. A secondary measure was the reduction in markers of oxidative stress.

## Statistical analysis

The study was originally designed to enroll 68 patients. On the basis of previous data (13), the sample size was calculated to provide a statistical power of 90% to detect an absolute difference between the 2 groups of 20% in  $T_3$  levels (assuming a two-sided level  $\alpha < .05$ ) using EpiInfo StatCalc (version 7.1.3). Categorical data are presented as frequencies and their differences were analyzed using the  $\chi^2$  or Fisher's exact test. Quantitative data with normal distribution are presented as mean  $\pm$  SD, and their differences were analyzed using the Student's *t* test. Non-parametric variables are presented as median  $\pm$  interquartile range and analyzed by Mann-Whitney's *U* test or repeated-measures ANOVA. Outcomes were analyzed according to the intention-to-treat principle. Within each group, changes ( $\delta$ ) in oxidative markers were calculated by subtracting the baseline values from the values measured after the intervention. Between-group differences were calculated by subtracting the change observed in the NAC group from the change observed in the placebo group. A value of  $P < .05$  was considered significant. The analyses were performed by PASW statistics version 18.0.

## Results

### Patients

Sixty-eight patients were randomly assigned to receive NAC or placebo. One patient in the placebo group died during the initial evaluation. Therefore, the study data included 67 patients (Figure 1). The mean age was  $57.2 \pm 9$  years, and 78% of the patients were male. The mean time from symptom onset was  $6.3 \pm 3$  hours, and most patients were classified as low risk, according to the Thrombolysis In Myocardial Infarction (TIMI) risk score (ST elevation  $\leq 3$  in 53% of patients). There were no significant differences between the groups with respect to any of the characteristics listed (Table 1).

### NAC prevents the decrease in serum $T_3$ and promotes decreases in $rT_3$ levels

In the placebo group, we observed a decrease in serum  $T_3$  at 6 hours (98.7–88.6 ng/dL;  $P = .001$ ) and 12 hours (98.7–86.8 ng/dL;  $P = .001$ , Figure 2A). Serum  $T_3$  re-


**Table 1.** Clinical and Baseline Laboratory Characteristics of the Study Population

	NAC (n = 34)	Placebo (n = 33)	P Value
Age, y	56.9 ± 9.4	57.4 ± 8.4	.80
Sex, % male	80	75	.56
Body mass index, kg/m <sup>2</sup>	26.8 ± 4.4	27.1 ± 3.5	.88
Hypertension, %	66	64	.60
Diabetes, %	39	32	.61
Heart failure, %	6.6	9	.67
Angina pectoris, %	50	42	.62
Time of presentation, h	5.7 ± 2.9	6.5 ± 2.9	.29
Troponin T, pg/mL	3029.8 ± 3122.3	3139.7 ± 2368.3	.87
KILLIP 1–2, %	100	93	.27
TIMI 0–3, %	53	53	.99
Median arterial pressure, mm Hg	96.6	95.2	.76
TSH, $\mu$ IU/mL	1.7 ± 1.2	1.6 ± 1.1	.82
T <sub>4</sub> , $\mu$ g/dL	7.4 ± 1.9	7.4 ± 1.4	.21
T <sub>3</sub> , ng/dL	100.4 ± 16.5	98.7 ± 20.7	.70
FT <sub>4</sub> , ng/dL	1.1 ± 0.2	1.1 ± 0.3	.82
rT <sub>3</sub> , ng/dL	54.7 ± 8.11	55.2 ± 6.1	.57

Reference ranges are as follows: serum FT<sub>4</sub>, 0.7–1.5 ng/dL; T<sub>4</sub>, 4.5–12 ng/dL; T<sub>3</sub>, 77–180 ng/dL; and rT<sub>3</sub>, 10–24 ng/dL.

turned to baseline levels at 48 hours (96.5 ng/dL) and did not change between 48 and 120 hours (96.5 to 94.2 ng/dL,  $P > .05$ ). In the group treated with NAC, there was no significant change in serum T<sub>3</sub> levels (100.4 to 94.2 to 97 to 93.5 to 92.0 ng/dL;  $P > .05$ ; Figure 2A). Compared with

the NAC-treated patients, the serum T<sub>3</sub> levels in the placebo group were lower at 6 hours (94.2 vs 88.6 ng/dL  $P < .001$ ) and 12 hours (97 vs 86.8 ng/dL;  $P < .001$ ; Figure 2A). Serum T<sub>3</sub> was similar between groups at 48 hours and on the fifth day of follow-up.



**Figure 2.** Changes in thyroid hormone levels in patients with acute myocardial infarction who received NAC treatment or placebo. Serum T<sub>3</sub> levels decreases at 6 and 12 hours in the placebo group but not in patients who received NAC (A). No significant changes were observed in serum rT<sub>3</sub> levels in the placebo group, whereas rT<sub>3</sub> decreased in a time-dependent fashion in NAC-treated patients (B). The T<sub>3</sub> to rT<sub>3</sub> ratio increases progressively in NAC-treated patients, whereas it remains stable in the placebo group (C). Neither group showed significant changes in serum FT<sub>4</sub> levels (D). \*,  $P < .001$ .

Considering that the decreases in serum  $T_3$  correlate with disease severity, we sought also to investigate the NAC effect on a subgroup of sickest patients. Thus, patients were grouped as moderate to high (TIMI score  $\geq 4$ ) or low (TIMI score  $\leq 3$ ) risk. Indeed, the average decrease in serum  $T_3$  levels at 12 hours in the moderate- to high-risk placebo subgroup ( $n = 16$ ) was more pronounced as compared with the low-risk subgroup ( $n = 17$ ; 19.9 vs 10.9%; 99.3 to 75.5 vs 98.1 to 88.2 ng/dL;  $P = .003$ ). Importantly, in the subgroup of moderate- to high-risk NAC-treated patients ( $n = 16$ ), there was no significant changes in serum  $T_3$  levels (103.9 to 92.1 to 93.8 to 85.6 to 88.5 ng/dL,  $P = .537$ ), demonstrating that NAC administration was able to prevent the  $T_3$  decreases.

The baseline serum  $rT_3$  levels were 3- to 4-fold elevated in both groups, relative to healthy subjects (14.2 vs 55.2 vs 52.7 ng/dL;  $P < .001$ ; Figure 2B). No significant changes were observed in the serum  $rT_3$  levels in the placebo group during the follow-up period (55.2 to 57.5 to 58.4 to 48.5 to 50 ng/dL;  $P = .75$ ; Figure 2B). In contrast, in the group treated with NAC, serum  $rT_3$  levels decreased in a time-dependent fashion, reaching the lowest value at 120 hours (52.7 to 43.8 to 33.7 to 29 to 22 ng/dL;  $P = .003$ ; Figure 2B). Accordingly, as compared with the placebo group, serum  $rT_3$  levels were lower in NAC-treated patients at 12 (50.7 vs 33.7 ng/dL,  $P = .003$ ) and 48 hours (48.5 vs 29 ng/dL,  $P = .05$ ).

Accordingly, although the  $T_3$  to  $rT_3$  ratio remained low and stable in the placebo group (1.8 to 1.5 to 1.4 to 1.7 to 1.8;  $P = .6$ ; Figure 2C), it increased over time in the NAC-treated patients (1.9 to 2.1 to 3.1 to 3.2 to 4.1;  $P < .001$ ; Figure 2C). Compared with the NAC-treated patients, the  $T_3$  to  $rT_3$  ratio in the placebo group were lower at all times evaluated ( $P < .001$ ).

No significant changes were observed in serum FT4 levels in the placebo group throughout the follow-up period (1.12 to 1.11 to 1.16 to 1.12 ng/dL, at baseline, 6, 12, and 48 h, respectively;  $P = .84$ ; Figure 2D). Interestingly, although not statistically significant upon post hoc testing, we observed an increase at 6 and 12 hours in serum FT4 in patients who received NAC (1.10 to 1.23 to 1.23 to 1.13 ng/dL;  $P = .06$ ; Figure 2D). There were no differences in serum FT4 levels between the groups ( $P = .11$ ).

### **NAC treatment does not alter the pituitary-thyroid feedback mechanism**

In the placebo group, we observed a progressive increase in the mean serum TSH levels during the follow-up period (1.6 to 2.5 to 3.9  $\mu$ IU/mL; at baseline, 48 h, and on the fifth day, respectively;  $P < .001$ ). Similar increases in serum TSH were observed in patients who received NAC (1.7 to 2.3 to 4.0  $\mu$ IU/mL; at baseline, 48 h, and on the fifth

day, respectively;  $P < .001$ ). Serum TSH values were virtually identical between the groups ( $P = .82$ ).


### **NAC administration normalizes the oxidative parameters in patients with AMI**

Next, we evaluated the oxidative status of the patients. As compared with healthy subjects, the initial total amount of intra- and extracellular antioxidant molecules (TAS) was reduced in placebo and NAC-treated groups (2.90 vs 1.75 vs 1.64 mmol/mg  $\cdot$  protein respectively,  $P < .002$ ; Figure 3A). No significant changes occurred in serum TAS levels in the placebo group (1.75 to 1.78 to 1.70 mmol/mg  $\cdot$  protein,  $P = .75$ ; Figure 3A). In contrast, in the NAC group, the serum TAS increased significantly, reaching the levels observed in healthy controls (1.64 to 2.93 to 2.5 mmol/mg  $\cdot$  protein,  $P < .001$ ; Figure 3A). The TAS concentrations were significantly higher in the NAC-treated patients at 6 hours (1.78 vs 2.93 mmol/mg  $\cdot$  protein;  $P = .008$ ) and 12 hours (1.70 vs 2.50 mmol/mg  $\cdot$  protein;  $P = .03$ ) of follow-up.

We also measured total carbonyl content, a parameter of protein oxidation. This was initially elevated in placebo and NAC groups, as compared with healthy subjects (0.46 vs 1.32 vs 1.4 nmol/mg  $\cdot$  protein, respectively,  $P < .001$ ) but did not differ between the placebo and NAC groups (Figure 3B). In the placebo group, no significant changes were observed in the total carbonyl content during the observational period (1.32 to 1.31 to 1.51 to 0.85 nmol/mg  $\cdot$  protein, at baseline, 6 h, 12 h, and 48 h, respectively;  $P = .11$ ; Figure 3B). However, in patients receiving NAC, the total carbonyl content decreased significantly, reaching normal levels by 48 hours (1.4 to 0.6 to 0.8 to 0.5 nmol/mg  $\cdot$  protein, at baseline, 6 h, 12 h, and 48 h, respectively;  $P < .001$ ; Figure 3B). The total carbonyl content was lower all times after initiating NAC treatment (Figure 3B).

### **NAC administration does not alter the acute phase response in AMI patients**

Next, we measured the serum IL-6 levels to evaluate the NAC effect in the acute phase response of AMI patients. The baseline serum IL-6 levels were elevated in both groups, as compared with healthy subjects (3.4 vs 49.3 vs 48.8 ng/L, respectively,  $P < .001$ ). We observed a progressive increase in IL-6 levels from baseline to 12 hours in both placebo and NAC-treated groups (49.3 to 50.1 to 74 ng/L,  $P = .02$ ; 48.8 to 58.6 to 81 ng/L,  $P < .02$ , respectively, Figure 4). In both groups, a subsequent decrease in mean serum IL-6 levels occurred at 48 hours and continued to drop reaching the baseline values at 120 hours (49.3 to 50.1 to 74 to 42.8 to 31 and 48.8 to 58.5 to 81 to 58.3 to 40 ng/L, respectively, Figure 4). No significant differ-



**Figure 3.** Oxidative stress biomarkers in patients with AMI who received NAC treatment or placebo. No significant changes occurred in serum TAS levels in the placebo group, whereas in the NAC group, TAS increased significantly, reaching the levels observed in healthy individuals (A). No significant changes were observed in the total carbonyl content in the placebo group, whereas the total carbonyl content decreased significantly and reached the levels observed in healthy subjects in NAC-treated patients (B).

ences were observed between the groups ( $P = .6$ ). Interestingly, however, the IL-6 levels were inversely correlated with  $T_3$  levels in the placebo group ( $r = -0.54$ ,  $P = .001$ ) but not in the NAC-treated patients ( $r = -0.04$ ,  $P = .86$ ).

### Adverse events and safety

The average length of hospital stay was 4.94 days in the placebo group and 4.24 days in the NAC-treated patients ( $P = .13$ ). Two patients in the control group but none in the NAC group required vasopressors. There were no deaths during the follow-up period.

### Discussion

The NTIS affects approximately 70% of patients with AMI and the serum  $T_3$  concentration correlates inversely with mortality (3, 5). Increased reactive oxygen species (ROS) generation, as observed in many diseases, disrupts


deiodinase function and may well play a central role in the derangement of peripheral thyroid hormone metabolism. Here we have demonstrated that the administration of NAC, a potent intracellular antioxidant, prevents the characteristic changes in serum  $T_3$  and  $rT_3$  during NTIS by the correction of the oxidative stress imbalance.

NTIS encompasses a number of changes in thyroid hormone physiology. The most striking alterations are the decreases in serum  $T_3$  and increases in  $rT_3$  levels observed in a variety of illness situations (14). These alterations are observed in the first hours of the disease and are among the last to recover (1, 15). The degree of reduction in thyroid hormone levels in sick patients is correlated with prognosis and survival (3, 16). A prospective observational study involving 480 unselected intensive care unit (ICU) patients has demonstrated that free  $T_3$  was the only independent predictor of ICU mortality (16).

In the present study, we planned to determine whether NAC administration could prevent the characteristic thyroid hormonal changes seen in individuals with AMI. We show that patients who received

NAC virtually eliminated the decrease in serum  $T_3$  levels observed in the placebo group. Moreover, in the NAC-treated group, we also observed a prevention of the increase in serum  $rT_3$ , which have declined to nearly normal levels (Figure 2). Both the fall in  $T_3$  and the increase in  $rT_3$ , which occur uniformly in sick patients as a mark of NTIS, can be attributed to changes in the peripheral metabolism of thyroid hormones. Indeed, early reports have demonstrated that decreased  $T_3$  production and increased  $rT_3$  concentrations developed rapidly in AMI patients (17), whereas studies performed in critically ill patients demonstrated a down-regulation of the hepatic D1 activity as well as an induction in liver and skeletal muscle D3 activity (18).

One puzzling observation in this study was the persistence of high  $rT_3$  levels in the placebo group, notwithstanding there was a near normalization of  $T_3$  levels starting at 48 hours (Figure 2, A and B). There are several



**Figure 4.** Serum IL-6 levels in patients with AMI who received NAC treatment or placebo. In both groups, the levels of IL-6 increases from baseline to 12 hours. A subsequent decrease in occurred at 48 hours and continued to drop, reaching the baseline values at 120 hours. No significant differences were observed in serum IL-6 levels between the groups.

potential possibilities for this finding. The D2 enzyme catalyzes only outer-ring deiodination of  $T_4$  to  $T_3$ , but D1 deiodinates  $T_4$  approximately equally at the outer and inner ring in vitro (19). On the other hand,  $rT_3$  is favored as a substrate for D1, and an increase in its activity will accelerate  $rT_3$  clearance. Assuming a recovery of activity of both D1 and D2, this will increase the  $T_3$  to  $rT_3$  ratio. On the other hand, D3 activity might also be increased in liver, which would generate more  $rT_3$  than degrade  $T_3$ . The balance between all of these interweaving iodothyronine degradation pathways in vivo is admittedly difficult to predict, but the best index of the whole process should be the ratio of circulating  $T_3$  to  $rT_3$ . Indeed, the  $T_3$  to  $rT_3$  ratio in the placebo group was virtually identical at 12, 48, and 120 hours and remains much lower than in the NAC patients, demonstrating that the peripheral hormone ratio abnormalities are still not better without NAC out to 120 hours (Figure 2C). Of interest, recent data from animal models also showed high D3 levels associated with increased cardiomyocyte thyroid hormone inactivation after myocardial infarction, but this is likely to have a greater effect on the local myocardial intracellular  $T_3$  concentration than that in the circulation (20).

Due to the importance of differentiating between reduction of  $T_4$  transport into cells to be activated into  $T_3$  vs a derangement in the  $T_4$ -to- $T_3$  activation process, we also evaluated serum FT4 concentrations in these patients. No significant differences in serum FT4 levels were observed between the groups, although we have detected a slightly increase FT4 in patients who received NAC. These observations support the idea that the most probable mechanism responsible for the acute NTIS is indeed the impaired peripheral  $T_4$ -to- $T_3$  conversion and  $rT_3$  clearance and not a reduction in  $T_4$  availability (21). Consistent with the

concept that the regulation of neuroendocrine feedback is a marker of recovery from acute illness, although not suppressed on admission, the progressive increase in TSH from the baseline to the fifth day of follow-up indicates that the predominant derangement in this moderately stressful illness is in peripheral thyroid hormone metabolism. The contrast used for the coronary angiography procedure did not appear to have a major effect, although it was received by both groups (22).

Oxidative stress, due to augmented ROS or reactive nitrogen species generation is observed in many diseases that are associated with NTIS (23). Patients usually have reduced plasma and intracellular levels of antioxidant scavenging molecules, including GSH, as well as decreased activity of the antioxidant enzymatic system involved in ROS detoxification (24). We have recently shown that the changes in the intracellular redox state, as observed in critically ill patients, reduces the serum  $T_3$  to  $T_4$  ratio due to the inhibition of deiodinase function, reducing D1- and D2-mediated  $T_4$ -to- $T_3$  conversion as well as increasing D3-mediated  $T_3$  (and  $T_4$ ) inactivation, thus mimicking events during illness (9).

To further demonstrate the correlation between the derangement in the redox status and changes in thyroid hormone levels, we measured biomarkers of oxidative stress. In addition, we measured the levels of IL-6, to evaluate the NAC effect on the overall acute-phase response in AMI patients. As expected, total carbonyl content was elevated and TAS was diminished at baseline, relative to normals, in all patients. However, those patients who received NAC had a reduction in the carbonyl content and return of TAS to levels in healthy volunteers. No differences were observed in serum IL-6 values between the placebo and NAC-treated groups (Figure 4). Taken together, these results demonstrate that oxidative stress occurred early in the course of AMI, and the administration of NAC was able to protect proteins from oxidative damage as well as correct the impaired total body antioxidant capacity. Notably, these results were paralleled, in a timely fashion, with serum thyroid hormone adjustment, suggesting that the  $T_3$  decrease is mainly due to oxidative stress-induced impairment of thyroid hormone activation (9). Although a potential effect of the cellular redox imbalance on  $T_4$  transport into cells could also contribute to the effect, previous studies in critically ill patients did not show a correlation between monocarboxylate transporter 8 expression and the ratio of the serum to tissue concentration of the different iodothyronines (25, 26).

There are several mechanisms by which low thyroid function might alter myocardial cells. Apart from the tissue consequences of decreased cardiac energetic efficiency, a low serum  $T_3$  may alter cardiac contractility and

heart rhythm. More recently reduced T<sub>3</sub> has been implicated in the process of myocardial hypertrophy and fibrosis as well as in the altered vasoactive properties of vessels (27, 28). Despite the importance of thyroid hormones homeostasis for cardiac function and the poor prognosis associated with NTIS in patients with ischemic heart disease, a treatment for NTIS has never been tested in patients with AMI. Long-term thyroid hormone administration has been shown to improve chronic cardiac function in post-myocardial infarction heart failure in rats (29, 30), but experience with hormone replacement in humans is limited. Studies in patients undergoing cardiac surgery and in patients with severe congestive heart failure have demonstrated hemodynamic benefit, with a reduced need for inotropic agents (31–33). The lack of benefit in the long-term outcomes and concerns about adverse effects, such as increased myocardial demand, arrhythmias and suppression of the hypothalamic-pituitary-thyroid axis, have reduced enthusiasm for T<sub>3</sub> administration in acute settings.

This study was limited to the assessment to the effect of NAC on the thyroid hormone economy during illness and not designed to evaluate the cardiac response to the use of NAC or whether NAC administration had effects on patient outcome. Nevertheless, it is worth mentioning that in vitro studies have shown that ROS mediates myocardial injury secondary to ischemia and reperfusion and activates fibrogenic pathways that favor adverse ventricular remodeling and cardiac dysfunction (34–37). However, antioxidant therapy for ischemic cardiovascular disease has produced controversial results to date. Arstall et al (38) showed that adjunctive therapy with NAC reduces oxidative stress markers and improved left ventricular function. In contrast, other studies failed to demonstrate clinical benefit with respect to myocardial reperfusion injury, despite the NAC-induced decreases in oxidative stress markers (10).

In conclusion, we demonstrate that NAC administration will rapidly reverse the acute derangements in thyroid hormone levels produced by the oxidative stress in patients with acute myocardial infarction. These findings have potential clinical relevance because low T<sub>3</sub> concentrations are associated with a poor outcome in acute and long-term cardiovascular events.

## Acknowledgments

This study was registered as Clinical Trials number NCT01501110.

Address all correspondence and requests for reprints to: Ana Luiza Maia, MD, PhD, Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, CEP 90035-003 Porto Alegre, RS, Brasil. E-mail: [almaia@ufrgs.br](mailto:almaia@ufrgs.br).

This work was supported from grants provided by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Apoio a Pesquisa do Rio Grande do Sul, Fundo de Incentivo a Pesquisa do Hospital de Clínicas of Brazil, and National Institute of Diabetes and Digestive and Kidney Diseases Grant 44128.

Disclosure Summary: The authors have nothing to declare.

## References

1. Larsen PR, Davies TF, Schlumberger MJ, Hay IA. Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. *Williams Textbook of Endocrinology*. Philadelphia: Saunders Elsevier; 2008:499–542.
2. Romijn JA, Wiersinga WM. Decreased nocturnal surge of thyrotropin in nonthyroidal illness. *J Clin Endocrinol Metab*. 1990;70:35–42.
3. Iervasi G, Pingitore A, Landi P, et al. Low-T<sub>3</sub> syndrome: a strong prognostic predictor of death in patients with heart disease. *Circulation*. 2003;107:708–713.
4. Pavlou HN, Kliridis PA, Panagiotopoulos AA, Goritsas CP, Vassilakos PJE. Euthyroid sick syndrome in acute ischemic syndromes. *Angiology*. 2002;53:699–707.
5. Iervasi G, Molinaro S, Landi P, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. *Arch Intern Med*. 2007;167:1526–1532.
6. Adawiyah J, Norasyikin AW, Mat NH, Shamsul AS, Nor Azmi K. The non-thyroidal illness syndrome in acute coronary syndrome is associated with increased cardiac morbidity and mortality. *Heart Asia*. 2010;2:11–14.
7. Wajner SM, Maia AL. New Insights toward the acute non-thyroidal illness syndrome. *Front Endocrinol (Lausanne)*. 2012;26:3–8.
8. Maia AL, Goemann IM, Meyer EL, Wajner SM. Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. *J Endocrinol*. 2011;209:283–297.
9. Wajner SM, Goemann IM, Bueno AL, Larsen PR, Maia AL. IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells. *J Clin Invest*. 2011;121:1834–1845.
10. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) trial. *J Am Coll Cardiol*. 2010;55:2201–2209.
11. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. *N Engl J Med*. 2006;354:2773–2782.
12. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. *Clin Sci (Lond)*. 1993;84:407–412.
13. Pimentel RC, Cardoso GP, Escosteguy CC, Abreu LM. Thyroid hormone profile in acute coronary syndromes. *Arq. Bras. Cardiol*. 2006;87:688–694.
14. Friberg L, Werner S, Eggertsen G, Ahnve S. Rapid downregulation of thyroid hormones in acute myocardial infarction. *Arch Intern Med*. 2002;162:1388–1394.
15. Chopra IJ. Clinical review 86: Euthyroid sick syndrome: is it a misnomer? *J Clin Endocrinol Metab*. 1997;82:329–334.
16. Wang F, Pan W, Wang H, Wang S, Pan S. Relationship between



- thyroid function and ICU mortality: a prospective observation study. *Critical Care*. 2012;16:R11.
17. Kaplan MM, Schimmel M, Utiger RD. Changes in serum 3,3',5'-triiodothyronine (reverse T3) concentrations with altered thyroid hormone secretion and metabolism. *J Clin Endocrinol Metab*. 1977;45:447–456.
  18. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. *J Clin Endocrinol Metab*. 2003;88:3202–3211.
  19. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. *J Clin Invest*. 2005;115:2524–2533.
  20. Pol CJ, Muller A, Simonides WS. Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptive response or part of the problem? *Heart Fail Rev*. 2010;15:133–142.
  21. Kaptein EM, Robinson WJ, Grieb DA, Nicoloff JT. Peripheral serum thyroxine, triiodothyronine and reverse triiodothyronine kinetics in the low thyroxine state of acute nonthyroidal illnesses. A noncompartmental analysis. *J Clin Invest*. 1982;69:526–535.
  22. Hintze G, Blombach O, Fink H, Burkhardt U, Kobberling J. Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects. *Eur J Endocrinol*. 1999;140:264–267.
  23. Abilés J, de la Cruz AP, Castaño J, et al. Oxidative stress is increased in critically ill patients according to antioxidant vitamins intake, independent of severity: a cohort study. *Crit Care*. 2006;10:R146.
  24. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic Biol Med*. 2001;30:1191–1212.
  25. Lima de Souza EC, Groeneweg S, Visser WE, Peeters RP, Visser TJ. Importance of cysteine residues in the thyroid hormone transporter MCT8. *Endocrinology*. 2013;154:1948–1955.
  26. Peeters RP, van der Geyten S, Wouters PJ, et al. Tissue thyroid hormone levels in critical illness. *J Clin Endocrinol Metab*. 2005;90:6498–6507.
  27. Kim BB, Ku YH, Han JY, et al. Relation of triiodothyronine to subclinical myocardial injury in patients with chest pain. *Am J Cardiol*. 2013;111:1087–1091.
  28. Pol CJ, Muller A, Zuidwijk MJ, et al. Left-ventricular remodeling after myocardial infarction is associated with a cardiomyocyte-specific hypothyroid condition. *Endocrinology*. 2011;152:669–679.
  29. Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV. Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. *Basic Res Cardiol*. 2008;103:308–318.
  30. Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM. Physiological replacement of T-3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. *Circ Heart Fail*. 2009;2:243–252.
  31. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. *N Engl J Med*. 1995;333:1522–1527.
  32. Choi YS, Kwak YL, Kim JC, Chun DH, Hong SW, Shim JK. Perioperative oral triiodothyronine replacement therapy to prevent postoperative low triiodothyronine state following valvular heart surgery. *Anaesthesia*. 2009;64:871–877.
  33. Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. *J Clin Endocrinol Metab*. 2008;93:1351–1358.
  34. Raedschelders K, Ansley DM, Chen DDY. The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. *Pharmacol Ther*. 2012;133:230–255.
  35. Gurusamy N, Das DK. Autophagy, redox signaling, and ventricular remodeling. *Antioxid Redox Signal*. 2009;11:1975–1988.
  36. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. *Cardiovasc Res*. 2009;81:482–490.
  37. Hori M, Nishida K. Oxidative stress and left ventricular remodeling after myocardial infarction. *Cardiovasc Res*. 2009;81:457–464.
  38. Arstall MA, Yang J, Stafford I, Betts WH, Horowitz JD. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. *Circulation*. 1995;92:2855–2862.